Difference between revisions of "Sunitinib"
Jump to navigation
Jump to search
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Sunitinib''' (marketed with the brand name ''Sutent'') is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC). | '''Sunitinib''' (marketed with the brand name ''Sutent'' by Pfizer) is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC). | ||
In RCC acts on:<ref>{{Cite journal | last1 = Toon | first1 = CW. | last2 = Hasovits | first2 = C. | last3 = Paik | first3 = J. | last4 = Field | first4 = M. | last5 = Chou | first5 = A. | last6 = Hugh | first6 = TJ. | last7 = Pavlakis | first7 = N. | last8 = Gill | first8 = AJ. | title = Skin rash, a kidney mass and a family mystery dating back to World War II. | journal = Med J Aust | volume = 201 | issue = 1 | pages = 58-60 | month = Jul | year = 2014 | doi = | PMID = 24999901 }}</ref> | In RCC acts on:<ref>{{Cite journal | last1 = Toon | first1 = CW. | last2 = Hasovits | first2 = C. | last3 = Paik | first3 = J. | last4 = Field | first4 = M. | last5 = Chou | first5 = A. | last6 = Hugh | first6 = TJ. | last7 = Pavlakis | first7 = N. | last8 = Gill | first8 = AJ. | title = Skin rash, a kidney mass and a family mystery dating back to World War II. | journal = Med J Aust | volume = 201 | issue = 1 | pages = 58-60 | month = Jul | year = 2014 | doi = | PMID = 24999901 }}</ref> | ||
| Line 5: | Line 5: | ||
*PDGFbeta. | *PDGFbeta. | ||
==Uses== | |||
*[[Gastrointestinal stromal tumour]], imatinib-resistant.<ref>{{Cite journal | last1 = Mulet-Margalef | first1 = N. | last2 = Garcia-Del-Muro | first2 = X. | title = Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. | journal = Onco Targets Ther | volume = 9 | issue = | pages = 7573-7582 | month = | year = 2016 | doi = 10.2147/OTT.S101385 | PMID = 28008275 }}</ref> | |||
*[[Renal cell carcinoma]] - especially [[clear cell renal cell carcinoma]].<ref name=pmid25075067>{{Cite journal | last1 = Yildiz | first1 = I. | last2 = Ekenel | first2 = M. | last3 = Akman | first3 = T. | last4 = Kocar | first4 = M. | last5 = Uysal | first5 = M. | last6 = Kanitez | first6 = M. | last7 = Varol | first7 = U. | last8 = Bayoglu | first8 = IV. | last9 = Tural | first9 = D. | title = Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. | journal = Anticancer Res | volume = 34 | issue = 8 | pages = 4329-34 | month = Aug | year = 2014 | doi = | PMID = 25075067 }}</ref> | |||
==See also== | ==See also== | ||
*[[Tyrosine kinase inhibitors]]. | *[[Tyrosine kinase inhibitors]]. | ||
Latest revision as of 19:57, 8 November 2018
Sunitinib (marketed with the brand name Sutent by Pfizer) is a tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC).
In RCC acts on:[1]
- VEGF.
- PDGFbeta.
Uses
- Gastrointestinal stromal tumour, imatinib-resistant.[2]
- Renal cell carcinoma - especially clear cell renal cell carcinoma.[3]
See also
References
- ↑ Toon, CW.; Hasovits, C.; Paik, J.; Field, M.; Chou, A.; Hugh, TJ.; Pavlakis, N.; Gill, AJ. (Jul 2014). "Skin rash, a kidney mass and a family mystery dating back to World War II.". Med J Aust 201 (1): 58-60. PMID 24999901.
- ↑ Mulet-Margalef, N.; Garcia-Del-Muro, X. (2016). "Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives.". Onco Targets Ther 9: 7573-7582. doi:10.2147/OTT.S101385. PMID 28008275.
- ↑ Yildiz, I.; Ekenel, M.; Akman, T.; Kocar, M.; Uysal, M.; Kanitez, M.; Varol, U.; Bayoglu, IV. et al. (Aug 2014). "Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.". Anticancer Res 34 (8): 4329-34. PMID 25075067.